AI assistant
IDEXX LABORATORIES INC /DE — Director's Dealing 2023
Dec 6, 2023
30016_dirs_2023-12-06_7cfbb13e-ec55-44b1-a950-b83cd4054945.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: IDEXX LABORATORIES INC /DE (IDXX)
CIK: 0000874716
Period of Report: 2023-12-04
Reporting Person: MAZELSKY JONATHAN JAY (Director, President and CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-12-04 | Common Stock | M | 13424 | $79.54 | Acquired | 86361.3456 | Direct |
| 2023-12-04 | Common Stock | S | 5804 | $512.95 | Disposed | 80557.3456 | Direct |
| 2023-12-04 | Common Stock | S | 1324 | $513.51 | Disposed | 79233.3456 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2023-12-04 | Non-Qualified Stock Option (right-to-buy) | $79.54 | M | 13424 | Disposed | 2025-02-13 | Common Stock (13424) | Direct |
Footnotes
F1: Includes 12 shares purchased under the Issuer's Employee Stock Purchase Plan on September 29, 2023.
F2: Represents the weighted average price of the shares sold ranging from a low of $512.35 to a high of $513.35 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F3: Represents the weighted average price of the shares sold ranging from a low of $513.36 to a high of $513.76 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F4: Grant of option to buy 13,424 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five annual installments beginning on February 14, 2016 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
F5: Not applicable.